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The Rotavirus Efficacy and Safety Trial (REST) was a blinded, placebo-controlled
study of the live pentavalent human-bovine vaccine, RotaTeq (Merck & Co. Inc.,
West Point, PA). REST was noteworthy because its primary objective was to evaluate
the safety of RotaTeq with regard to intussusception, a rare intestinal illness that
occurs with a background incidence of approximately 50 cases per 100000 infant
years. The study involved approximately 70000 infants at over 500 study sites in
11 countries. The study demonstrated that the risk of intussusception was similar in
vaccine and placebo recipients and that the vaccine prevented rotavirus gastro-
enteritis, ameliorated the severity of disease in those who had any disease, and
substantially reduced rotavirus-associated hospitalizations and other health care
contacts. This report provides an in-depth review of the background, statistical and
regulatory considerations, and execution of REST. We describe the rationale and
methods used for sample size, continuous safety monitoring, group sequential
design, and detailed study execution. The results of the study have been
reported elsewhere. The design and conduct of this study may serve as a
useful model for planning other future large-scale clinical trials, especially those
evaluating uncommon adverse events. Clinical Trials 2008; 5: 131–139. http://
ctj.sagepub.com
Introduction
Rotavirus is the leading cause of hospitalization
and death from acute gastroenteritis among
infants and young children worldwide [1,2]. In
1998, a tetravalent rhesus-human reassortant
rotavirus vaccine (RRV-TV; RotaShield, Wyeth
Laboratories) was licensed and recommended by
the Advisory Committee for Immunization
Practices (ACIP) for routine immunization of
infants in the United States [3]. However, post-
marketing surveillance studies detected a temporal
association between RRV-TV and intestinal intus-
susception, the telescoping or prolapse of one
portion of the bowel into an immediately adjacent
segment. Intussusception is an uncommon illness
with a background incidence of 18–56 cases
per 100000 infant years during the first year of
life in the US [4]. The population attributable risk
detected in the postmarketing studies for RRV-TV
was approximately 1 additional case per 10000
vaccine recipients [5–8]. No association between
RRV-TV and intussusception was observed in
clinical studies conducted prelicensure [9].
Clinical studies did show that a higher proportion
of RRV-TV recipients than non-RRV-TV recipients
had gastrointestinal illnesses (including vomiting,
diarrhea, abdominal pain, and bloody stools), as
well as fever [10–13]. RRV-TV was voluntarily
withdrawn from the market in October 1999 and
2 weeks later the ACIP rescinded its recommenda-
tion for universal vaccination.
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ception and RRV-TV, clinical development of
RotaTeq, a pentavalent human-bovine reassortant
rotavirus vaccine (PRV, Merck & Co., Inc.,
West Point, PA) was in phase II trials. Various
formulations of PRV showed good efficacy ( 70%
reduction of episodes of rotavirus gastroenteritis of
any severity and 100% reduction of episodes of
severe disease) and that the incidence of fever and
gastrointestinal symptoms was generally similar
among vaccine and placebo recipients [14]. A deci-
sion was made to continue the PRV program
because of the importance of a safe and effective
rotavirus vaccine to public health [15–17]. The
absence of an apparent association between wild-
type human rotavirus disease and intussusception
indicated that intussusception would not necessa-
rily be associated with all rotavirus vaccines [9,18].
Furthermore, preclinical data suggested that there
might be some biological differences between
PRV and RRV-TV [19, Merck unpublished data].
However, evaluation of the safety of the vaccine
with respect to intussusception became a critical
question in the clinical development plan, and a
large-scale prelicensure safety study was deemed
necessary.
The Rotavirus Efficacy and Safety Trial (REST)
was a double-blinded (operating under sponsor
blinding procedures), placebo-controlled study
conducted in 11 countries at over 500 study sites.
Study subjects were randomized at a 1:1 ratio to
receive either the final formulation of PRV or
placebo. The study involved approximately 70000
subjects (including over 35000 infants (50%) from
the United States), making it one of the largest
vaccine clinical trials ever conducted prelicensure.
The trial demonstrated that the risk of intussuscep-
tion was similar in recipients of PRV and recipients
of placebo. It also demonstrated that PRV pre-
vented rotavirus gastroenteritis and ameliorated
the severity of disease in those who had any
disease, through the use of a validated scoring
system. Furthermore, collection of data on health
care encounters among all 70000 subjects demon-
strated that the vaccine substantially reduced
rotavirus-associated hospitalization and other
health care contacts. The details of the study results
have been published elsewhere [20].
This report provides an in-depth review of the
statistical, safety, and regulatory considerations
involved in the design of the study and the details
of the execution of REST. This trial was notable for
its design, large sample size, detailed execution,
continuous safety monitoring, and lengthy dura-
tion. The design and conduct of this study may
serve as a useful tool for planning other future
clinical trials, especially those evaluating uncom-
mon adverse events.
Methods
Key criteria in the design of REST
The primary event of interest in REST was the
incidence of intussusception following receipt of
PRV or placebo. Intussusception has a clear case
definition, and therefore, there was a high level of
confidence that if intussusception did occur follow-
ing vaccination, it could be readily detected.
Furthermore, it was known that there were specific
time intervals during which the potential risk of
intussusception is greatest, both in terms of the age
at which intussusception occurs naturally in young
infants as well as the time period following RRV-TV
when the majority of cases occurred. Thus, a clear
case definition and time periods of interest could be
easily specified. However, the design of REST faced
3 main challenges: (1) Study Design Considerations:
To design a study that was large enough to provide
a meaningful evaluation of the risk of an uncom-
mon event, intussusception, yet was feasible to
implement prelicensure, (2) Safety Considerations:
To develop a continuous safety monitoring system
that would insure a high level of confidence in
detecting cases of intussusception and identifying
any potential increased risk of intussusception
early so as to minimize the risk to trial participants,
and (3) Regulatory Considerations: To conduct
a study that would be acceptable to the regulatory
community and provide adequate information
for licensure decisions. The method by which
each of these challenges was addressed in the
design of REST is described in further detail
subsequently.
Study design considerations
The important aspects of the study design included
the age at which subjects would be vaccinated,
their duration of follow-up, the primary hypoth-
esis, the interim monitoring by the DSMB, the
statistical model used, and the sample size. The
specifics of each of these aspects are discussed
below.
Age at vaccination
PRV was intended to be used as a 3-dose regimen in
infants as part of the routine childhood immu-
nization schedule administered within the first
6 months of life. In this study, it was specifically
decided to limit the administration of the first dose
of PRV to the period from 6 to 12 weeks of age
with subsequent doses at 4- to 10-week intervals.
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associated hospitalizations occurs among infants
and young children 6–24 months of age. Thus, it
was desired to vaccinate early so as to provide
protection at a young age. Completion of the
3-dose regimen within the prespecified time
period insured that study participants received all
three doses prior to the age of greatest risk of
rotavirus gastroenteritis.
This time period is also prior to the period when
the background rate of intussusception increases
substantially. The background rate of naturally
occurring intussusception is fairly low in infants
<4 months of age (50 per 100000 person years),
with the rate increasing with age [9]. Restriction of
vaccination to the prespecified time period allowed
for rapid identification of a possible increase in
intussusception with vaccination, should one exist.
If intussusception cases were observed in infants at
this young age when the background rates are low,
it would have been a signal of a possible increased
risk of intussusception which would have led to
stopping the study early.
Duration of follow-up
The duration of safety follow-up after administra-
tion of each dose of vaccine/placebo was established
as 42 days because this time period has traditionally
been used for observation of adverse events follow-
ing live virus vaccines. It was also chosen because
it was possible that the cases of intussusception
following PRV might occur within a different time
frame than those observed after vaccination with
RRV-TV. Although the majority of cases of intus-
susception following RRV-TV occurred within the
first 7 days after vaccination, it was possible that
because PRV was less reactogenic and only elicited a
minimal amount of vaccine viral replications in the
intestinal tract, cases of intussusception might be
seen later than those following RRV-TV. However,
because the risk of intussusception associated with
RRV-TV was highest during the week after vacci-
nation, the incidence of intussusception following
PRV was also evaluated for the 7 days after
vaccination. For long-term evaluation of intussus-
ception, all subjects were to be followed for 1 year
after the first vaccination, or until the end of the
closure of the study site, whichever occurred first.
Primary hypothesis and utilization of group
sequential design
The primary safety objective of the study was to
demonstrate with a high level of confidence that
the vaccine had a clinically acceptable safety profile
for licensure. This would be shown analytically
with the lack of a statistically increased risk and
also a low level of risk within the period following
vaccination when the vaccine is biologically active.
Safety endpoints other than intussusception were
also collected and analyzed thoroughly, but the
study design was driven primarily by intussuscep-
tion. The primary safety hypothesis was that PRV
would not increase the risk of intussusception
relative to placebo within 42 days after any dose.
In order to satisfy the primary safety hypothesis,
two criteria needed to be met:
1) Throughout the study, the vaccine/placebo case
ratio could not reach predefined unsafe bound-
aries being monitored by the Data Safety
Monitoring Board (DSMB) within 42 days
following any dose or within 7 days following
any dose.
2) At the end of the study, the upper bound of the
95% confidence interval (CI) estimate of the
relative risk of intussusception was  10 within
42 days following any dose.
These criteria were developed by the sponsor and
were part of the study protocol. They were
supported by the DSMB for use as their guidelines.
It is well understood by clinical trial statisticians
that a single study can never prove the absence of
risk. This is especially the case when evaluating
uncommon adverse events like intussusception, as
in REST. The study design used an end-of-study
criterion threshold of risk based on the expected
low background rate of intussusception. The suc-
cess of the study was based on simultaneously
satisfying the two criteria listed above. For the end-
of-study criterion, the study employed a group
sequential design, which called for a minimum of
60000 infants with complete safety follow-up, and
subsequent groups of 10000 infants if the end of
study criterion was not met, up to a maximum
sample size of 100000. These design factors are
discussed more fully later in this report.
For the interim safety monitoring, the boundary
points were chosen to detect a statistically signifi-
cant increase in relative risk. In other words, the
boundary points corresponded to the lower bound
of the 95% CI for relative risk of intussusception
among vaccine as compared with placebo recipi-
ents being >1.0at any point in the study; these
boundary points were intentionally chosen without
regard to multiplicity in order to be conservative.
If at any time during the study this boundary was
reached for the 7-day or 42-day periods after any of
three doses, the DSMB could recommend stopping
the study due to safety concerns.
Rotavirus efficacy and safety trial 133
http://ctj.sagepub.com Clinical Trials 2008; 5: 131–139The use of 10 as the upper bound criterion at the
end of the study was chosen due to the relatively
few intussusception cases expected in the study.
Given the number of cases expected, vaccine/
placebo risk ratios that were considered clinically
acceptable were defined statistically as those relative
risk estimates having an upper bound of the 95%
confidence interval  10. The study was planned
assuming a background incidence of 50 cases per
100000 person years and an exposure window of
102 days, allowing for 30 days post dose 1, 30 days
post dose 2, and 42 days post dose 3. (A conservative
30day post doses 1 and 2 time period was used in
planning the study to accommodate the vaccine
schedules for some of the countries participating in
the study.) For a provisional starting sample size of
60000, the expected number of total intussuscep-
tion cases occurring during the 42-day period
following any dose of vaccine/placebo was 8,
assuming that the vaccine did not increase the risk
of intussusception. With 8 observed cases, a case
split of 4 vaccine to 4 placebo cases (relative risk of
1) or more favorable was needed to satisfy the
primary safety hypothesis at the end of the study.
With 10–12 observed cases, relative risks of  2 were
needed in order for the upper bound to be  10.
Therefore, only a small relative risk would allow
for a conclusion that the vaccine had an acceptable
safety profile.
Statistical model
The basic statistical model for the study assumed
that numbers of cases of intussusception were
distributed as Poisson random variables with rate
parameters lV and lC for vaccine (V) and placebo
(C) recipients, respectively. Then, conditional on
the total number of intussusception cases, the
number of vaccine cases is distributed as a binomial
with parameters t¼VþC and  ¼lV/(lVþlC).
Using this model, the relationship between the
relative risk R¼lV/lC and   are given by
R ¼
 
ð1    Þ
and   ¼
R
ð1 þ RÞ
:
Exact binomial inference was then utilized with t
and  .
For the interim safety monitoring, the boundary
points were chosen to detect a statistically signifi-
cant increase in relative risk in vaccine compared to
placebo recipients. For t total accrued intussus-
ception cases, the boundary point was the small-
est number of vaccine cases v such that Pt
x¼v Bðxjt, Þ 0:025, where B(x|t, ) represents
the probability of observing x vaccine cases
among t assuming a binomial proportion  . The
day 1–42 boundary, shown in Figure 1(a), corre-
sponds to  ¼0.5. The day 1–7 boundary compared
the number of vaccine cases occurring 1–7 days
after any dose to the number of placebo cases
occurring 1–42 days after any dose; the day range
for the placebo cases remained 1–42 in order to
increase the power of this safety monitoring
through use of more potential cases. Thus,
Figure 1(b) was computed for this scenario using
 ¼21/102¼0.171 to account for the differential
exposure time in vaccine and placebo recipients.
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Figure 1 Predefined safety boundaries for the 42 and 7day ranges after any dose: (a) 42-day period after any dose, (b) 7-day
period after any dose
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ment in accordance with the group sequential
design was based on satisfying the upper bound of
the 95% confidence interval estimate of relative risk
being  10. The shaded region in Figure 2 shows
case splits meeting this criterion. As previously
discussed, the vaccine/placebo case splits that make
up this region represent estimates of relative risk
that also would be considered clinically acceptable
for licensure. This region was also determined using
exact binomial methods, with the impact of the
interim stopping rules for negative results being
considered. Because the study used interim stop-
ping rules for negative results that were appropri-
ately strict (and stricter than rules designed just to
accept the primary null hypothesis) and that
covered two different day ranges (1–7 and 1–42),
the group-sequential region of acceptance could
not be determined using standard design techni-
ques. Instead, the region was chosen according to
that defined by the maximum number of vaccine
cases v such that
Pv
x¼0 Bðxjt,  ¼ 0:9091Þ 0:025,
corresponding to a relative risk of 10, and then
evaluation of the design properties was done via
simulation (described below) in order to account
for the interim monitoring. The terminal P-value,
point estimate, and confidence interval estimate of
the relative risk were appropriately adjusted based
on the group-sequential aspect of the design using
the methodology described in Jennison and
Turnbull [21].
The REST study design had two simultaneous
goals: (1) A high probability that if the vaccine was
associated with an increased risk of intussusception
this would be detected quickly and the study would
be stopped early, and (2) A high probability that a
safe vaccine would meet the end of study criteria.
The statistical operating characteristics of REST were
estimated using Monte Carlo simulation. Each
simulation run generated 10000 random sequences
of vaccine and placebo cases. For each sequence, it
was determined whether the sequence caused the
study to (1) stop early according to the two safety
monitoring boundaries, or (2) satisfy the primary
safety criteria for stopping the study. Figure 3 shows
the probability of each possible outcome for
different levels of relative risk. For a vaccine with
no increased risk of intussusception, there was a
0.06 probability that the study would stop early due
to a safety concern, and a 0.94 probability of
successfully reaching the end-of-study criterion.
Figure 3 also shows the important role of the
continuous safety monitoring in drawing a study
conclusion. The probability of stopping the study
early for safety concerns increased substantially for
relative risks in the range of 2.5–6. For relative risks
of 6 or greater, the study would have ended early
almost with certainty. The simulation also allowed
varying the relative risk profile over intervals of time
through the follow-up period. This feature of the
simulation was important in that it allowed model-
ing the risk profile reported for the RRV-TV in the
CDC case-control and case series studies [7]. The
same five intervals (1–2 days, 3–7 days, 8–14 days,
15–21 days, and 22–42 days) following each of the
three doses were used. The probability of reaching
one of the two unsafe boundaries was 0.85 for
the CDC case-control profile and 0.91 for the CDC
case-series profile.
Safety considerations
Three elements were critical to the safety surveil-
lance used in this study: (1) Active and passive
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Figure 2 Criteria for stopping enrollment (based on primary
hypothesis)
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Figure 3 Statistical operating characteristics for REST study
design
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susception, (2) Extensive interim safety monitor-
ing, and (3) Early termination of the study, if
deemed necessary. Although not a formal part of
the safety monitoring system established to address
intussusception, another consideration was the
ability to generate adequate general safety data to
support licensure at the end of the study.
Active and passive safety surveillance
In order to evaluate the primary safety objective,
all subjects in the study were to be followed for
intussusception for a minimum of 42 days follow-
ing any vaccination. Active follow-up was emplo-
yed throughout the 4-year study to insure a high
level of detecting cases of intussusception. The
parent/legal guardian was instructed to report any
potential case of intussusception that occurred at
any time to the study site. Study sites were required
to implement a rigorous program of active safety
follow-up for intussusception. This included tele-
phone contacts or home visits on Days 7, 14, and
42 following vaccination to ask about potential
cases of intussusception or any other serious
adverse experience. If a case of intussusception
was reported to the study site, the study site was
requested to report the case within 24h to the
sponsor.
Additional safety surveillance was conducted
every 6 weeks from day 43 after dose 3 to day 365
after dose 1 or until the study sites end-of-study
date, whichever came first. This surveillance was
conducted in order to assess any potential cases of
intussusception that may have occurred in the year
after dose 1. The parent/legal guardian was con-
tacted every 6 weeks by an electronic or postal
mailing, telephone call, home visit, or during a
physician’s office visit and asked about potential
cases of intussusception.
Rigorous safety surveillance throughout this
4-year study was critical. Study sites were chosen
on the basis of a good standard of care for the
treatment of intussusception and the ability to
conduct extensive surveillance rather than on the
ability to enroll large numbers of infants. In order
to assure that study personnel performed all
planned safety contacts throughout the study,
centralized computer or manual tracking systems
were initiated in every country. These systems were
developed so that the study sites were reminded
when the day 7, day 14, and day 42 contacts, and
subsequent 6 week contacts were scheduled for
each subject. If contacts were not made within a
prespecified timeframe ( 1day for the Day 7, 14,
and 42 contacts and  2 weeks for the 6 week
contacts), then the study personnel received
a reminder notice. It was also important that
subjects were not lost to follow-up. At a minimum,
safety follow-up was needed for 42 days after any
vaccination. Throughout the study, detailed
instructions were provided to study site personnel
on how to pursue subjects who were potentially
lost to follow-up including additional phone calls,
mailing of registered letters, and home visits, as
appropriate. If a subject was truly lost to follow-up,
the sponsor was contacted within 24h. This rigo-
rous active surveillance system ensured that the
data on potential intussusception cases and other
serious adverse experiences were as complete as
possible. Using these multiple follow-up methods,
safety follow-up was completed for >99.9% of
subjects enrolled in the study.
In addition to the active surveillance that was
performed, a passive surveillance system was devel-
oped for all parents/guardians. All parents/
guardians were provided with the definition of
gastroenteritis (a stomach illness with diarrhea and/
or vomiting) and the signs/symptoms of intussus-
ception. Each parent/guardian was asked to notify
study personnel if a subject had symptoms compa-
tible with intussusception or was admitted to the
hospital or seen in the emergency room for
gastroenteritis. Each parent also received a study
card that could be used to notify health care
personnel that a subject was participating in this
trial. The card instructed the health care profes-
sional in how to contact study personnel should
their patient have any illness that might be
intussusception. All illnesses that were reported
in which the diagnosis of intussusception was
considered, even if the final diagnosis was not
intussusception, were assessed.
Interim safety monitoring by SEAC and DSMB
A blinded Safety Endpoint Adjudication
Committee (SEAC) reviewed each potential case
of intussusception when it was reported. A stan-
dard operating procedure, which included defini-
tive clinical, radiographic, surgical, and pathology
guidelines for the diagnosis of intussusception, was
used by the SEAC when adjudicating each poten-
tial case of intussusception. The positively adjudi-
cated cases meeting the predefined case definition
were then forwarded to a separate, independent
Data Safety Monitoring Board (DSMB).
The DSMB was instituted in order to detect a
potential increased risk of intussusception early
and minimize the risk to trial participants if the
risk of intussusception was deemed unacceptable.
The DSMB unblinded the treatment group for
each positively adjudicated intussusception case
when it was reported and made recommendations
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DSMB plotted the occurrence of each case of intus-
susception on the graphs shown in Figure 1(a) and
(b) for the 7- and 42-day timeframes following
vaccination, respectively. The DSMB then utilized
the predetermined stopping boundaries in
these figures to determine whether there was a sta-
tistically significant increase (lower bound of
the 95% CI>1.0) in intussusception risk among
vaccine as compared to placebo recipients. These
criteria were used in concert with clinical judgment
when making interim recommendations regarding
study continuation.
The DSMB also met every 6 months over the
course of the 4-year study to review all safety data
to determine if there were any other adverse events
of concern.
Finally, the DSMB made recommendations to
the sponsor regarding the completion of the overall
enrollment with respect to the group sequential
design based on whether the criterion for stopping
enrollment associated with the primary safety
hypothesis had been satisfied (Figure 2).
Regulatory considerations
The design of REST was discussed with several
regulatory agencies prior to study start. In the
United States, the design of the study was formally
presented to the Vaccines & Related Biologics
Product Advisory Committee (VRBPAC) in May
2000. At this meeting, it was incumbent on the
sponsor to propose specific criteria to demonstrate
the safety of the vaccine for licensure. Those criteria
(described earlier in this document) were unan-
imously approved by VRBPAC along with the study
design. VRBPAC also requested that revisions be
made to the consent form for the study to
adequately inform parents/guardians of the safety
issues being evaluated among study participants.
Numerous discussions were held with the
Centers for Biologics Evaluation & Research
(CBER) prior to study start in January 2001. The
regulatory authorities requested a full review of all
prior safety data for the vaccine. They also asked
the sponsor to demonstrate a high level of
confidence that the vaccine was safe while mini-
mizing the risk to participants in the REST trial.
In addition to the standard collection of data on
serious adverse experiences from all subjects, the
sponsor was asked to solicit detailed safety data on
5000–10000 susceptible infants gathered from
blinded, placebo-controlled studies. The safety
criteria for the vaccine were discussed in-depth
at a workshop convened by FDA, the National
Institutes of Health (NIH), and the Centers
for Disease Control and Prevention (CDC) in
November 2001 to evaluate the safety of new
vaccines [22]. All of this regulatory input was
addressed in the design of the study.
Discussion and conclusions
REST utilized a unique study design. Since it was
necessary to both detect an elevated risk of
intussusception at an early stage and to demon-
strate that the safety profile of the vaccine was
acceptable for licensure, a novel study design was
necessary. Specifically, a continuous monitoring
boundary was used in conjunction with a group-
sequential design. The monitoring boundary was
designed to detect an elevated risk in intussuscep-
tion during biologically and clinically important
timeframes while the group sequential design, with
its large sample size and possibility of expanding
enrollment to accrue more cases of intussusception,
allowed for the demonstration of safety at the end
of the study. Both the monitoring boundary and
the group sequential design were critical to the
demonstration of an acceptable product safety
profile to support licensure and acceptance in the
medical community.
Group-sequential designs had not been routinely
used in clinical trials of new drugs or vaccines at the
time REST was designed. This type of design has its
pros and cons. The advantage of using this design is
that it has the potential to draw a conclusion based
on a more efficient sample size. The initial sample
size for REST was 60000 subjects, but an additional
10000 subjects had to be enrolled because the
criteria for stopping enrollment according to the
primary endpoint was not met based on 60000
subjects. Had this study been conducted using a
classical fixed subject statistical design, the sample
size would have been  85000 subjects.
The disadvantage of the group sequential design
is that the actual duration of the study and the
study budget cannot be predetermined, resulting in
the need to work within a range of study comple-
tion dates and a range of possible study costs.
Uncertainty regarding the timing of study results,
let alone the results themselves, can have a major
impact on key decisions in moving a product
forward, particularly with respect to investing in
new manufacturing facilities and the need to
develop backup compounds.
The detailed analysis of the association between
intussusception and RRV-TV conducted prior to the
start of this study necessitated the successful design
of REST. Based on the previous experience with
RRV-TV, we designed a study of PRV in which the
age and timing at which intussusception occurred
with RRV-TV was covered. Had the prelicensure
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design, it is likely ( 85%) the studies of RRV-TV
would have been stopped due to a safety concern,
based on the safety boundaries, as was shown by
the simulation results.
The success of this study was possible not only
because of its large sample size but also because of
the excruciating attention to detail employed in
the study’s execution. Extensive systems were utili-
zed to track each subject in the trial. The success
of these systems was shown by the remarkably
low rate of subjects lost to follow-up (<0.1%).
A low loss to follow-up rate is particularly
important when trying to evaluate an uncommon
serious adverse event such as intussusception.
Furthermore, the reporting of potential cases of
intussusception was handled in a conservative
manner so that it was highly unlikely that a case
could be missed. These methods, in conjunction
with the routine involvement of the SEAC and
DSMB in the evaluation of every possible case of
intussusception, resulted in a very complete safety
monitoring system.
A basic question in evaluating any new drug or
vaccine is how much safety data are enough. REST
was one of the largest prelicensure studies ever
conducted for a vaccine. The prelicensure safety of
most new vaccines is based on a sample size of
 5000–10000 subjects. The fact that this study
was designed to address a specific concern over the
relationship of PRV and intussusception and that
no relationship was identified when comparing
 35000 vaccine recipients to  35000 placebo
recipients provides substantial reassurance to
health care professionals, parents, and regulatory
agencies of the safety of this vaccine. Nevertheless,
postlicensure safety studies of PRV were still
requested by regulatory agencies to gather addi-
tional information on the safety of the vaccine due
to possible differences in the characteristics of
infants who receive the vaccine in routine use
compared with infants in clinical trials. Two con-
trolled studies are now ongoing with this vaccine,
one in a health maintenance organization con-
ducted by the manufacturer involving approxi-
mately 44000 subjects and one using the Vaccine
Safety Datalink (VSD) cosponsored by FDA and
CDC involving approximately 90000 subjects.
Both studies use a continuous monitoring of
intussusception cases as they accrue with a pre-
established safety boundary to alert investigators
of any increased risk. In total, the safety data from
pre- and postlicensure controlled studies will
include over 169000 recipients of PRV, a remark-
ably large number. The data obtained to date from
the postlicensure studies confirm the excellent
safety profile of the vaccine and lack of association
with intussusception demonstrated in the prelicen-
sure studies.
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